Protection from diabetes-induced atherosclerosis and renal disease by d-carnosine-octylester: effects of early vs late inhibition of advanced glycation end-products in Apoe-null mice

被引:57
作者
Menini, Stefano [1 ]
Iacobini, Carla [1 ]
Ricci, Carlo [1 ]
Fantauzzi, Claudia Blasetti [1 ]
Pugliese, Giuseppe [1 ]
机构
[1] Univ Roma La Sapienza, Dept Clin & Mol Med, I-00189 Rome, Italy
关键词
Advanced glycation end-products; AGE; Atherosclerosis; Carnosine; Reactive carbonyl species; Renal disease; GLUCOSE CONTROL; RECEPTOR; COMPLICATIONS; ENDPRODUCTS; REDUCTION; LESIONS; STRESS; INJURY;
D O I
10.1007/s00125-014-3467-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
AGEs are involved in diabetic complications and might be responsible for the phenomenon of 'hyperglycaemic memory'. d-Carnosine-octylester (DCO) has been shown to attenuate AGE formation and vascular and renal injury induced by high-fat diet in Apoe-null mice. This study aimed to verify the protective effect of DCO in atherosclerosis and renal disease induced by experimental diabetes and to discover whether reduction of AGE formation by early vs late DCO treatment provides better macro and microvascular protection. Apoe-null mice were rendered diabetic by streptozotocin and were left untreated or were treated with DCO for 20 weeks (DCO-Extended), from week 1 to 11 (DCO-Early) or from week 9 to 19 (DCO-Late). Non-diabetic Apoe-null mice served as controls. Aortic and renal lesions were evaluated by morphometry and protein and gene expression of disease markers were assessed by immunohistochemistry and real-time PCR. DCO-Extended treatment produced a more stable plaque phenotype by markedly attenuating diabetes-induced increases in lesion size, necrotic core area and plaque content of N epsilon-carboxymethyllysine, levels of apoptotic cells and markers of inflammation and oxidative stress and also reductions in collagen and smooth muscle cells. DCO treatment for 11 weeks afforded partial protection and this was significantly better in DCO-Early mice than in DCO-Late mice. Renal disease was attenuated in DCO-Extended mice and to a lesser extent in those treated for 11 weeks, with no significant difference between DCO-Early mice and DCO-Late mice. These data show that DCO protects mice from diabetes-induced vascular and renal disease and that protection against atherosclerosis is more effectively achieved by early treatment than by late treatment, thus suggesting that early inhibition of AGE formation attenuates progression of macroangiopathy and favours development of more stable lesions.
引用
收藏
页码:845 / 853
页数:9
相关论文
共 36 条
[1]   Advanced glycation endproducts - role in pathology of diabetic complications [J].
Ahmed, N .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2005, 67 (01) :3-21
[2]   Carnosine and related dipeptides as quenchers of reactive carbonyl species: From structural studies to therapeutic perspectives [J].
Aldini, G ;
Facino, RM ;
Beretta, G ;
Carini, M .
BIOFACTORS, 2005, 24 (1-4) :77-87
[3]   The carbonyl scavenger carnosine ameliorates dyslipidaemia and renal function in Zucker obese rats [J].
Aldini, Giancarlo ;
Orioli, Marica ;
Rossoni, Giuseppe ;
Savi, Federica ;
Braidotti, Paola ;
Vistoli, Giulio ;
Yeum, Kyung-Jin ;
Negrisoli, Gianpaolo ;
Carini, Marina .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2011, 15 (06) :1339-1354
[4]  
[Anonymous], NEW ENGL J MED
[5]   Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes [J].
Basta, G ;
Schmidt, AM ;
De Caterina, R .
CARDIOVASCULAR RESEARCH, 2004, 63 (04) :582-592
[6]   L-carnosine and verapamil inhibit hypoxia-induced expression of hypoxia inducible factor (HIF-1α) in H9c2 cardiomyoblasts [J].
Bharadwaj, LA ;
Davies, GF ;
Xavier, IJ ;
Ovsenek, N .
PHARMACOLOGICAL RESEARCH, 2002, 45 (03) :175-181
[7]   Advanced Glycated End-Products Affect HIF-Transcriptional Activity in Renal Cells [J].
Bondeva, Tzvetanka ;
Heinzig, Juliane ;
Ruhe, Carola ;
Wolf, Gunter .
MOLECULAR ENDOCRINOLOGY, 2013, 27 (11) :1918-1933
[8]   A procedure for obtaining whole mount mouse aortas that allows atherosclerotic lesions to be quantified [J].
Brånén, L ;
Pettersson, L ;
Lindholm, M ;
Zaina, S .
HISTOCHEMICAL JOURNAL, 2001, 33 (04) :227-229
[9]   UKPDS and the legacy effect [J].
Chalmers, John ;
Cooper, Mark E. .
NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (15) :1618-1620
[10]  
Decker EA, 2000, BIOCHEMISTRY-MOSCOW+, V65, P766